HAIXI PHARMA (02637) saw its shares rise more than 8% after the company reported its financial results for the fiscal year 2025. As of the latest update, the stock was up 8.06%, trading at HK$172.9, with a turnover of HK$62.17 million. On March 31, HAIXI PHARMA announced its full-year performance, posting revenue of approximately RMB582 million, a year-on-year increase of 24.79%. Net profit reached about RMB177 million, up 30.09% compared to the previous year, with earnings per share at RMB2.55. The company attributed the revenue growth to enhanced marketing efforts during the year, which boosted sales of its products Haihuitong® and Anbili®. Notably, Haihuitong® was newly included in the National Volume-Based Procurement (VBP) program specification (5mg/20mg×14 tablets) in 2025, effectively driving expansion in hospital channels and boosting sales in the end market.